Rentschler Biopharma Announces Executive Board Changes and Next Phase of Corporate Strategy

Rentschler Biopharma SE announced Executive Board changes on January 20, 2026, as it implements the next phase of its corporate strategy for long-term growth and sustainable value creation.1 2

Benedikt von Braunmuehl stepped down as CEO by mutual agreement with the Supervisory Board.1 2 3

Uwe Buecheler, PhD, Vice Chairman of the Supervisory Board, appointed interim CEO effective immediately until a permanent successor is named.1 2 3

Christiane Bardroff, COO, will leave the company in Q1 2026 after four years; her successor appointed and to be announced soon.1 2

The company is in a strong operational and economic position, focusing on client satisfaction, production capacity scale-up, and business expansion under new leadership.1 2

Sources:

1. https://www.globenewswire.com/news-release/2026/01/20/3221961/0/en/Rentschler-Biopharma-Announces-Executive-Board-Changes-and-Next-Phase-of-Corporate-Strategy.html

2. https://www.rentschler-biopharma.com/en-us/news-events/press-releases/rentschler-biopharma-announces-executive-board-changes-and-next-phase-of-corporate-strategy/

3. https://pharmasource.global/content/news/cdmo-news/rentschler-biopharma-announces-ceo-transition/

Sources:

Leave a Reply Cancel reply